Orion secures license to Abzena’s next-generation cancer antibody
The antibody was designed and developed at Abzena’s Cambridge, UK,
The antibody was designed and developed at Abzena’s Cambridge, UK,
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
The new site enables end-to-end production of viral vector gene therapies
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Subscribe To Our Newsletter & Stay Updated